Completed PHASE1 INTERVENTIONAL 4-arm NCT02327000

A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers

Sponsor: GL Pharm Tech Corporation

Conditions Healthy

Interventions Pregabalin 150mg Pregabalin 300mg

Updated 5 times since 2017 Last updated: Dec 23, 2014 Started: Oct 31, 2014 Primary completion: Oct 31, 2014 Completion: Oct 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02327000, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by GL Pharm Tech Corporation, it has been updated 5 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GL Pharm Tech Corporation

Data source: GL Pharm Tech Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.